Abstract:618 Background: Previous studies have proved IAC could reduce the recurrence and progression of HR NMIBC. The KEYNOTE-057 study has supported the benefits of PD-1 inhibitor in HR NMIBC patients (pts). Our study was established to evaluate the efficacy and safety of IAC combined with tislelizumab and BCG as a bladder-preserving treatment for HR NMIBC pts. Methods: This open-label, single arm phase II study enrolled BCG-naïve HR NMIBC pts with papillary tumors (high-grade Ta or T1 tumors). Firstly, the papillary tumors should be removed all visible lesions by transurethral resection of bladder tumor (TURBT). Secondly, angiographic catheter was placed into the internal iliac arteries with Seldinger’s percutaneous technique, cisplatin (60 mg/m 2 ) and epirubicin (50 mg/m 2 ) were administered arterially in day 1 (D1), every 3 weeks for 2-4 cycles. And pts received tislelizumab 200 mg IVGTT in D1, every 3 weeks for 2-4 cycles. Finally, pts received 18 instillations of BCG plus at least 8 cycles of tislelizumab (200 mg IVGTT, every 3 weeks). Specifically, pts were started on an induction course of BCG with 6 instillations every week, followed by maintenance with 3 instillations every 2 weeks and 9 instillations every 4 weeks. The primary end point was disease-free survival (DFS) rate at 12 months (defined as no reappearance of high grade or T1 tumors or clinical stage development after the therapy). Secondary end points were bladder-preservation rate, OS and safety. Our study estimated a DFS rate at 12 months was no less than 55% and the study would enroll 27 pts. Results: By Sep. 2023, 13 eligible pts were enrolled. Ten pts were analyzed (male 80.0%; median age 58 years (39-77); pure TCC 80.0%; median tumor size 2.5 cm (0.6-5.4); multiple papillary tumours=60.0%; high-grade Ta=40.0%, T1=60.0%). Median follow-up was 16.4 months (10.8-33.9), the mean number of IAC cycles was 2.4, mean number of tislelizumab cycles was 15.8, and the median BCG instillations was 16 (11-18). The DFS rate at 12 month was 90.0% (95%CI, 71.5%-98.6%). One pt showed reappearance of high-grade Ta and received TURBT. The bladder-preservation rate at 12 months was 100% (95%CI, 100%-100%). The OS rate at 12 months was 100% (95%CI, 100%-100%). 3 pts experienced treatment related adverse events, including nausea (n=1, G2), myalgia (n=1, G2), fatigue (n=1, G2), neutropenia (n=1, G2) and fever (n=1, G3). Conclusions: Our preliminary results supported the use of IAC combined with tislelizumab and BCG as a promising bladder-preserving strategy for HR NMIBC pts. Clinical trial information: ChiCTR2200067146 .

A phase 2 pilot study of water irrigation after transurethral resection of bladder tumor (WATIP) demonstrating safety, feasibility and activity

Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors

Combination of Cystistat and Pirarubicin Intravesical Instillation in Reducing Intravesical Chemotherapy Complications: a Multi-Center Clinical Study

Should continuous bladder irrigation be recommended when single instillation of intravesical chemotherapy cannot be used after transurethral resection in low-risk non-muscle invasive bladder cancer?

Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis

Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study

Efficacy Of Immediate Instillation Combined With Regular Instillations Of Pirarubicin For Ta And T1 Transitional Cell Bladder Cancer After Transurethral Resection: A Prospective, Randomized, Multicenter Study

Intra-Arterial Chemotherapy for Muscle-Invasive Bladder Cancer Following Transurethral Resection

Single postoperative instillation for non-muscle invasive bladder cancer: are there still any indication?

Analysis of efficacy of transurethral resection in saline button electrode plasma vaporization in non-muscle-invasive bladder cancer

Observation of Immediate Intravesical Instillation of Pirarubicin in Preventing Non-Muscle-Invasive Bladder Cancer Relapse after Transurethral Resection of Bladder Tumor

Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.

Punch: Preliminary results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).

Sterile Water Versus Glycine in Transurethral Resection of Bladder Tumors—Immunogenic and Clinical Implications

Transurethral Resection of Bladder Tumor (TURBT) Followed by Partial Hypo-Fractionated Radiotherapy Concurrent with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer (MIBC): Acute Toxicities of a Prospective Phase II Study

Endoscopic balloon cryoablation plus transurethral resection for bladder cancer: A phase 2, multicenter, randomized, controlled trial

Hypo-Fractionated Radiotherapy Boost and Concurrent Chemo-Radiotherapy for Patients with Muscle-Invasive Bladder Cancer (MIBC): A Preliminary Report of the Prospective Phase II Study

Effectiveness of integrated nursing interventions in enhancing patient outcomes during postoperative intravesical instillation for non-muscle invasive bladder cancer: A comparative study

Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.

Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis

The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association–defined Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: A Phase 1b Study